Johnson & Johnson quarterly sales rise

Share this article:

Johnson and Johnson's second-quarter spreadsheet showed sales jumped 8.5% to $17.8 billion for the quarter, compared to $16.4 for the same period last year. Sales for the first six months of the year were also up 8.5%, hitting $35.3 billion, compared to $32.6 for the same period the year before. The uptick translated into a jump in profits—$3.8 billion for the quarter, and $7.3 billion for the six-month period—but as noted by Forbes, these numbers lose some of their heft due to “a brutal 2012” benchmark. Selling its share in Elan helped bolster the company's results.

Quarter standouts included an 8% bump in US consumer sales to $7.9 billion, compared to $7.3 billion for the same period last year. Numbers for the six-month mark were $15.9 billion in US sales compared to $14.5 billion and $35.3 billion in worldwide sales compared to $32.6 billion for the same period last year.

Over-the-counter sales rebounded, rising 5.4% worldwide to $931 million for the quarter, compared to $883 million for the same period last year. The company's pharmaceutical lineup included a 4% bump in Remicade sales to $926 million, compared to $890 million for the quarter ($1.6 billion worldwide compared to $1.5 billion), while Simponi sales rose 38% to $87 million for the quarter compared to $63 million ($175 million worldwide compared to $125 million) and Stelara sales jumped over 53% in the US to $233 million compared to $152 million ($371 million worldwide compared to $248 million).

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?